联合化疗方案剂量强度治疗对弥漫大B细胞淋巴瘤患者临床分析及预后的影响

Effect of Dose Strength Therapy Combined with Chemotherapy on the Clinical Analysis and Prognosis of Patients with Diffuse Large B Cell Lymphoma

目的探究在临床治疗弥漫大B细胞淋巴瘤患者的过程中,应用联合化疗方案剂量强度治疗的临床效果及其对预后的影响,为临床肿瘤的治疗奠定基础。方法选取2015年2月—2017年11月在该院治疗弥漫大B细胞淋巴瘤患者85例,随机分组治疗,其中试验组45例患者,对照组40例患者,分别予以不同的化疗方案并对比临床效果及预后情况。结果予以不同治疗方案后,试验组患者的临床有效率86.67%,显著高于对照组55.0%,差异有统计学意义(χ~2=9.264;P=0.001 6)。试验组患者的无进展及中位生存时间显著长于对照组,差异有统计学意义(t=10.027,11.244;P=0.003 7,0.001 6)。试验组患者的不良反应(恶心呕吐、血小板减少、白细胞减少等)发生率73.3%(33/45)均显著低于对照组45.0%(18/40),差异有统计学意义(χ~2=16.054;P=0.006)。试验组患者的IL-6、IL-10炎性因子表达情况均显著低于对照组,差异有统计学意义(t=29.341,22.455;P=0.002 7,0.001 3)。结论在临床治疗弥漫大B细胞淋巴瘤患者的过程中,应用联合化疗方案剂量强度治疗可显著改善患者各项炎性因子的表达情况,延长患者的生存、并减少不良反应,对患者的预后有很好的临床价值,值得临床推广。

Objective To explore the clinical effects and its effect on the prognosis of the treatment of diffuse large Bcell lymphoma in patients with clinically diffused B-cell lymphoma by combined dose chemotherapy. Methods 85 patients with diffuse large B-cell lymphoma treated in the hospital from February 2015 to November 2017 were randomized to receive treatment. 45 patients in the experimental group and 40 patients in the control group were treated with different chemotherapy regimens. Compare clinical effects and prognosis. Results After being given different treatment options, the clinical effectiveness 86.67% of the experimental group was significantly higher than that of the control group 55.0%. The difference was significant（χ^2=9.264; P =0.001 6）. The progression-free and median survival time were significantly longer in the experimental group than in the control group（t=10.027,11.244; P= 0.003 7, 0.001 6）.The incidence of adverse reactions（nausea and vomiting, thrombocytopenia, leukopenia, etc.） was significantly lower in the experimental group 73.3%（33/45） than in the control group 45.0%（18/40） the difference, with a significant difference（χ^2=16.054; P=0.006）. The expression of IL-6 and IL-10 in the experimental group was significantly lower than that in the control group（t=29.341, 22.455; P=0.002 7, 0.001 3）. Conclusion In the clinical treatment of patients with diffuse large B-cell lymphoma, the combination of chemotherapy dose intensity treatment can significantly improve the expression of various inflammatory factors, prolong survival and reduce adverse reactions, and the prognosis of patients.It has good clinical value and is worthy of clinical promotion.